Vertex Pharmaceuticals (VRTX) Receivables (2009 - 2026)

Vertex Pharmaceuticals' Receivables history runs 18 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• In Q1 2026, Receivables rose 10.58% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 10.58% YoY), while the FY2025 annual figure was $2.1 billion, up 27.55% from the prior year.
• Receivables was $2.0 billion for Q1 2026 at Vertex Pharmaceuticals, down from $2.1 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.1 billion in Q4 2025 to a low of $1.3 billion in Q1 2022.
• Historically, Receivables has averaged $1.7 billion across 5 years, with a median of $1.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Receivables jumped 43.45% in 2022, then advanced 0.66% in 2025.
• A 5-year view of Receivables shows it stood at $1.4 billion in 2022, then gained by 8.4% to $1.6 billion in 2023, then rose by 2.94% to $1.6 billion in 2024, then increased by 27.55% to $2.1 billion in 2025, then fell by 2.76% to $2.0 billion in 2026.
• The last three Receivables figures came in at $2.0 billion (Q1 2026), $2.1 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.